Roles and Potential Clinical Applications of Intermediate Filament Proteins in Brain Tumors

Snider, 2014, Post-translational modifications of intermediate filament proteins: Mechanisms and functions, Nat Rev Mol Cell Biol, 15, 163, 10.1038/nrm3753 Liberski, 1997, Ultrastructural pathology of glial brain tumors revisited: A review, Ultrastruct Pathol, 21, 1, 10.3109/01913129709023244 Alibardi, 2006, Structural and immunocytochemical characterization of keratinization in vertebrate epidermis and epidermal derivatives, Int Rev Cytol, 253, 177, 10.1016/S0074-7696(06)53005-0 Zuela, 2012, Lamins in development, tissue maintenance and stress, EMBO Rep, 13, 1070, 10.1038/embor.2012.167 Toivola, 2005, Cellular integrity plus: Organelle-related and protein-targeting functions of intermediate filaments, Trends Cell Biol, 15, 608, 10.1016/j.tcb.2005.09.004 Ho, 1996, Intermediate filaments in the nervous system: Implications in cancer, Cancer Metastasis Rev, 15, 483, 10.1007/BF00054014 Lépinoux-Chambaud, 2013, Review on intermediate filaments of the nervous system and their pathological alterations, Histochem Cell Biol, 140, 13, 10.1007/s00418-013-1101-1 Sultana, 2000, Intermediate filament protein synemin is transiently expressed in a subset of astrocytes during development, Glia, 30, 143, 10.1002/(SICI)1098-1136(200004)30:2<143::AID-GLIA4>3.0.CO;2-Z Izmiryan, 2010, Synemin isoforms in astroglial and neuronal cells from human central nervous system, Neurochem Res, 35, 881, 10.1007/s11064-009-0111-9 Human intermediate filament database. Available at: http://www.interfil.org/diseases.php. Accessed October, 2014 Röber, 1989, Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: A developmental study, Development, 105, 365, 10.1242/dev.105.2.365 Hutchison, 2014, Do lamins influence disease progression in cancer?, Adv Exp Med Biol, 773, 593, 10.1007/978-1-4899-8032-8_27 Chow, 2012, The nuclear envelope environment and its cancer connections, Nat Rev Cancer, 12, 196, 10.1038/nrc3219 Jing, 2005, Intermediate filament protein synemin is present in human reactive and malignant astrocytes and associates with ruffled membranes in astrocytoma cells, Glia, 50, 107, 10.1002/glia.20158 Skalli, 2013, Astrocytoma grade IV (glioblastoma multiforme) displays 3 subtypes with unique expression profiles of intermediate filament proteins, Hum Pathol, 44, 2081, 10.1016/j.humpath.2013.03.013 Dahlstrand, 1992, Expression of the class VI intermediate filament nestin in human central nervous system tumors, Cancer Res, 52, 5334 Mukasa, 2004, Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss, Brain Pathol, 14, 34, 10.1111/j.1750-3639.2004.tb00495.x Katsetos, 2002, Localization of the neuronal class III beta-tubulin in oligodendrogliomas: Comparison with Ki-67 proliferative index and 1p/19q status, J Neuropathol Exp Neurol, 61, 307, 10.1093/jnen/61.4.307 Phillips, 2006, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, Cancer Cell, 9, 157, 10.1016/j.ccr.2006.02.019 Ning, 2014, Oncolytic herpes simplex virus-based strategies: Toward a breakthrough in glioblastoma therapy, Front Microbiol, 5, 303, 10.3389/fmicb.2014.00303 Maguire, 2014, Gene therapy for the nervous system: Challenges and new strategies, Neurotherapeutics, 11, 817, 10.1007/s13311-014-0299-5 Kwiatkowska, 2013, Strategies in gene therapy for glioblastoma, Cancers, 5, 1271, 10.3390/cancers5041271 Rainov, 2000, A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme, Hum Gene Ther, 11, 2389, 10.1089/104303400750038499 Sandmair, 2000, Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses, Hum Gene Ther, 11, 2197, 10.1089/104303400750035726 Markert, 2009, Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM, Mol Ther, 17, 199, 10.1038/mt.2008.228 Vandier, 1998, Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simples virus-thymidine kinase gene, Cancer Res, 58, 4577 Vandier, 2000, Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter, Cancer Gene Ther, 7, 1120, 10.1038/sj.cgt.7700211 Kambara, 2005, An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor, Cancer Res, 65, 2832, 10.1158/0008-5472.CAN-04-3227 Prentice, 2011, Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease, Invest Ophthalmol Vis Sci, 52, 8562, 10.1167/iovs.10-6835 Boulaire, 2009, Transcriptional targeting to brain cells: Engineering cell type-specific promoter containing cassettes for enhanced transgene expression, Adv Drug Deliv Rev, 61, 589, 10.1016/j.addr.2009.02.007 Kim, 2014, Delivery of hypoxia and glioma dual-specific suicide gene using dexamethasone conjugated polyethylenimine for glioblastoma specific gene therapy, Mol Pharm, 11, 938, 10.1021/mp4006003 Wu, 2009, Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy, Mol Ther, 17, 2058, 10.1038/mt.2009.225 Restrepo, 2011, Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas, Neuro Oncol, 13, 42, 10.1093/neuonc/noq145 Ma, 2012, Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma, Neuro Oncol, 14, 1153, 10.1093/neuonc/nos145 Sultana, 1998, Effects of growth factors and basement membrane proteins on the phenotype of U-373MG glioblastoma cells as determined by the expression of intermediate filament proteins, Am J Pathol, 153, 1157, 10.1016/S0002-9440(10)65660-X Zhou, 2000, TGF-a differentially regulates GFAP, vimentin, and nestin gene expression in U-373MG glioblastoma cells: Correlation with cell shape and motility, Exp Cell Res, 254, 269, 10.1006/excr.1999.4762 Chang, 2013, Fibroblast growth factor-2 up-regulates the expression of nestin through the Ras-Raf-ERK-Sp1 signaling axis in C6 glioma cells, Biochem Biophys Res Commun, 434, 854, 10.1016/j.bbrc.2013.04.031 Shih, 2006, Notch signaling enhances nestin expression in gliomas, Neoplasia, 8, 1072, 10.1593/neo.06526 Ehrmann, 2005, Nestin as a diagnostic and prognostic marker: Immunohistochemical analysis of its expression in different tumours, J Clin Pathol, 58, 222, 10.1136/jcp.2004.021238 Strojnik, 2007, Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: Correlation of nestin with prognosis of patient survival, Surg Neurol, 68, 133, 10.1016/j.surneu.2006.10.050 Krupkova, 2010, Nestin expression in human tumors and tumor cell lines, Neoplasma, 57, 291, 10.4149/neo_2010_04_291 Arai, 2012, Nestin expression in brain tumors: Its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas, Brain Tumor Pathol, 29, 160, 10.1007/s10014-012-0081-5 Zhang, 2008, Nestin and CD133: Valuable stem cell-specific markers for determining clinical outcome of glioma patients, J Exp Clin Cancer Res, 27, 85, 10.1186/1756-9966-27-85 Kitai, 2010, Nestin expression in astrocytic tumors delineates tumor infiltration, Brain Tumor Pathol, 27, 17, 10.1007/s10014-009-0261-0 Wei, 2008, Nestin small interfering RNA (siRNA) reduces cell growth in cultured astrocytoma cells, Brain Res, 1196, 103, 10.1016/j.brainres.2007.11.026 Lu, 2011, Inducible expression of stem cell associated intermediate filament nestin reveals an important role in glioblastoma carcinogenesis, Int J Cancer, 128, 343, 10.1002/ijc.25586 Chou, 2003, Nestin promotes the phosphorylation-dependent disassembly of vimentin intermediate filaments during mitosis, Mol Biol Cell, 14, 1468, 10.1091/mbc.E02-08-0545 Jacque, 1978, Determination of glial fibrillary acidic protein (GFAP) in human brain tumors, J Neurol Sci, 35, 147, 10.1016/0022-510X(78)90107-7 Niu, 2011, Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells, Oncol Rep, 26, 593 Velasco, 1980, Immunohistochemical localization of glial fibrillary acidic protein in human glial neoplasms, Cancer, 45, 484, 10.1002/1097-0142(19800201)45:3<484::AID-CNCR2820450312>3.0.CO;2-9 Choi, 2009, Enhanced glial fibrillary acidic protein-delta expression in human astrocytic tumor, Neurosci Lett, 463, 182, 10.1016/j.neulet.2009.07.076 Heo, 2012, A histopathological diagnostic marker for human spinal astrocytoma: Expression of glial fibrillary acidic protein-delta, J Neurooncol, 108, 45, 10.1007/s11060-012-0801-z Rutka, 1997, Role of glial filaments in cells and tumors of glial origin: A review, J Neurosurg, 87, 420, 10.3171/jns.1997.87.3.0420 Rutka, 1994, Effects of antisense glial fibrillary acidic protein complementary DNA on the growth, invasion, and adhesion of human astrocytoma cells, Cancer Res, 54, 3267 Toda, 1999, Suppression of glial tumor growth by expression of glial fibrillary acidic protein, Neurochem Res, 24, 339, 10.1023/A:1022538810581 Elobeid, 2000, Effects of inducible glial fibrillary acidic protein on glioma cell motility and proliferation, J Neurosci Res, 60, 245, 10.1002/(SICI)1097-4547(20000415)60:2<245::AID-JNR14>3.0.CO;2-1 Wilhelmsson, 2003, Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression, Oncogene, 22, 3407, 10.1038/sj.onc.1206372 Ohgaki, 2007, Genetic pathways to primary and secondary glioblastoma, Am J Pathol, 170, 1445, 10.2353/ajpath.2007.070011 Middeldorp, 2011, GFAP in health and disease, Prog Neurobiol, 93, 421, 10.1016/j.pneurobio.2011.01.005 Roelofs, 2005, Adult human subventricular, subgranular, and subpial zones contain astrocytes with a specialized intermediate filament cytoskeleton, Glia, 52, 289, 10.1002/glia.20243 Moeton, 2014, Silencing GFAP isoforms in astrocytoma cells disturbs laminin-dependent motility and cell adhesion, FASEB J, 28, 2942, 10.1096/fj.13-245837 Jung, 2007, Serum GFAP is a diagnostic marker for glioblastoma multiforme, Brain, 130, 3336, 10.1093/brain/awm263 Brommeland, 2007, Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas, Acta Neurol Scand, 116, 380, 10.1111/j.1600-0404.2007.00889.x Husain, 2012, Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas, J Neurooncol, 109, 123, 10.1007/s11060-012-0874-8 Wei, 2013, Serum GFAP autoantibody as an ELISA-detectable glioma marker, Tumor Biol, 34, 2283, 10.1007/s13277-013-0770-7 Pan, 2008, Intermediate filament protein synemin contributes to the migratory properties of astrocytoma cells by influencing the dynamics of the actin cytoskeleton, FASEB J, 22, 3196, 10.1096/fj.08-106187 Foley, 2014, The non-muscle functions of actinins: An update, Biochem J, 459, 1, 10.1042/BJ20131511 Pitre, 2012, Synemin promotes AKT-dependent glioblastoma cell proliferation by antagonizing PP2A, Mol Biol Cell, 23, 1243, 10.1091/mbc.E11-08-0685 Mergui, 2010, p21Waf1 expression is regulated by nuclear intermediate filament vimentin in neuroblastoma, BMC Cancer, 10, 473, 10.1186/1471-2407-10-473 Marshall, 2010, TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells, Oncogene, 29, 6172, 10.1038/onc.2010.340 Maresca, 2012, LMNA knock-down affects differentiation and progression of human neuroblastoma cells, PLoS One, 7, e45513, 10.1371/journal.pone.0045513 Dehghani, 1998, Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: A study of 89 cases, Acta Neuropathol, 95, 493, 10.1007/s004010050830 Ducray, 2009, α-Internexin expression identifies 1p19q codeleted gliomas, Neurology, 72, 156, 10.1212/01.wnl.0000339055.64476.cb Ducray, 2011, Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas, Eur J Cancer, 47, 802, 10.1016/j.ejca.2010.11.031 Buckley, 2011, Loss of chromosome 1p/19q in oligodendroglial tumors: Refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker, J Neuropathol Exp Neurol, 70, 177, 10.1097/NEN.0b013e31820c765b Hadfield, 2003, Tubulin and microtubules as targets for anticancer drugs, Prog Cell Cycle Res, 5, 309 Zhou, 2005, Targeting microtubules for cancer chemotherapy, Curr Med Chem Anticancer Agents, 5, 65, 10.2174/1568011053352569 Hayot, 2006, Characterization of the activities of actin-affecting drugs on tumor cell migration, Toxicol Appl Pharmacol, 211, 30, 10.1016/j.taap.2005.06.006 Bargagna-Mohan, 2007, The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin, Chem Biol, 14, 623, 10.1016/j.chembiol.2007.04.010 Thaiparambil, 2011, Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation, Int J Cancer, 129, 2744, 10.1002/ijc.25938 Grin, 2012, Withaferin A alters intermediate filament organization, cell shape and behavior, PLoS One, 7, e39065, 10.1371/journal.pone.0039065 Nagalingam, 2014, Mechanistic elucidation of the antitumor properties of withaferin A in breast cancer, Cancer Res, 74, 2617, 10.1158/0008-5472.CAN-13-2081 Goldman, 1996, The function of intermediate filaments in cell shape and cytoskeletal integrity, J Cell Biol, 134, 971, 10.1083/jcb.134.4.971 Beck, 2011, Identification of a peptide that interacts with nestin protein expressed in brain cancer stem cells, Biomaterials, 32, 8518, 10.1016/j.biomaterials.2011.07.048 Bocquet, 2009, Neurofilaments bind tubulin and modulate its polymerization, J Neurosci, 29, 11043, 10.1523/JNEUROSCI.1924-09.2009 Balzeau, 2012, The vimentin-tubulin binding site peptide (Vim-TBS.58-81) crosses the plasma membrane and enters the nuclei of human glioma cells, Int J Pharm, 423, 77, 10.1016/j.ijpharm.2011.04.067 Lépinoux-Chambaud, 2013, The NFL-TBS.40-63 anti-glioblastoma peptide enters selectively in glioma cells by endocytosis, Int J Pharm, 454, 738, 10.1016/j.ijpharm.2013.04.004 Rivalin, 2014, The NFL-TBS.40-63 anti-glioblastoma peptide disrupts microtubule and mitochondrial networks in the T98G glioma cell line, PLoS One, 9, e98473, 10.1371/journal.pone.0098473 Berges, 2012, Structure-function analysis of the glioma targeting NFL-TBS.40-63 peptide corresponding to the tubulin-binding site on the light neurofilament subunit, PLoS One, 7, e49436, 10.1371/journal.pone.0049436